New Delhi/New York  – Tomorrow, MSF will defend the rights of millions of children around the world to be protected against pneumonia at a hearing at India’s Patent Office. In March, the organisation filed a ‘patent opposition’ to prevent US pharmaceutical company Pfizer from getting a patent on the pneumococcal conjugate vaccine (PCV13), so more affordable versions can become available to developing countries and humanitarian organisations.

Pneumonia is the leading cause of childhood death, killing almost one million children each year. Currently, pharmaceutical companies Pfizer and GlaxoSmithKline (GSK) are the only two manufacturers of the vaccine, which could prevent a large number of these deaths. Broad use of the vaccine could also reduce antibiotic use in children by 47 per cent each year in an analysis conducted in 75 countries, helping to stem the global rise of antibiotic resistance.  

Pfizer has priced the pneumonia vaccine, which it markets as Prevenar 13 out of reach of many developing countries and humanitarian organisations. At the lowest global price, it is now 68 times more expensive to fully vaccinate a child than in 2001, according to the 2015 MSF report, The Right Shot: Bringing down Barriers to Affordable and Adapted Vaccines, with the pneumonia vaccine accounting for almost half of the price of vaccinating a child in the poorest countries.

“The pneumonia vaccine is the world’s best-selling vaccine, and last year alone, Pfizer brought in more than US$6 billion dollars in sales just for this product – meanwhile many developing countries, where millions of children risk getting pneumonia, simply can’t afford it”, said Dr Greg Elder, Medical Coordinator for MSF’s Access Campaign. “To make sure children everywhere can be protected from deadly pneumonia, other companies need to be allowed to enter the market so they can supply this vaccine for a much lower price than Pfizer charges.”

One vaccine producer in India has already announced that it could supply the pneumonia vaccine for US$6 dollars per child (for all three doses) to public health programmed and humanitarian organisations like MSF. This is almost half the current lowest global price of US$10 dollars per child, which is only available to a limited number of developing countries via donor funding through Gavi, the Vaccine Alliance.

MSF’s challenge to Pfizer’s patent – a ‘pre-grant opposition’, which is a form of citizen review at the patent examination stage – shows that Pfizer’s patent application lacks technical merit. Simply adding six serotypes to a widely-used carrier protein (CRM197), in order to conjugate 13 serotypes of streptococcus pneumonia into a single carrier represents a step that is considered ‘obvious’ to skilled vaccine developers. Additionally, Pfizer’s response to the patent office does not provide sufficient evidence to support its claims.

“The pneumonia vaccine clearly does not merit patenting under India’s Patents Act and would only result in artificially prolonging Pfizer’s market monopoly, which keeps millions of children at risk of contracting this deadly killer”, said Leena Menghaney, Head of MSF’s Access Campaign in South Asia. “India must rebuff demands from pharmaceutical companies, and tackle low-quality patent applications which only add trivial technical changes and often deprive millions of people from accessing more affordable treatment and vaccines. Pfizer’s unmerited patent application on the pneumonia vaccine should be rejected, opening the door to more affordable versions of the vaccines being produced.”